+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Custom Polyclonal Antibody Production Service Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Custom Polyclonal Antibody Production Service Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
New

Custom Polyclonal Antibody Production Service Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • PDF Icon

    Report

  • 190 Pages
  • May 2025
  • Region: Global, United States
  • 360iResearch™
  • ID: 6081511
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
Custom polyclonal antibody production has evolved into a strategic imperative for organizations seeking reliable immunological reagents tailored to complex research, diagnostic, and therapeutic applications. In an era defined by precision medicine, point-of-care testing, and cutting-edge proteomic analysis, the demand for high-quality polyclonal sera has soared. Manufacturers and service providers are challenged to balance stringent regulatory expectations with accelerated development timelines and cost pressures. Concurrently, advancements in antigen design, immunization protocols, and purification technologies have enabled unprecedented specificity and yield. As a result, stakeholders must navigate a dynamic environment where scientific rigor, operational efficiency, and ethical considerations around animal welfare intersect. This introduction outlines the key factors driving market maturation, highlights the critical role of custom antibody solutions in advancing life sciences, and sets the stage for a deeper exploration of the transformative trends, regulatory headwinds, market segmentation, and competitive dynamics that define the contemporary landscape.

Transformative Shifts Redefining the Polyclonal Antibody Market

Over the past five years, several transformative shifts have redefined how custom polyclonal antibody services are designed and delivered. First, next-generation antigen selection leveraging recombinant proteins and synthetic peptides has increased both the breadth and reproducibility of immune responses. In parallel, high-throughput screening platforms-ranging from ELISA-based assays to hybridoma screening pipelines-have compressed lead times from months to weeks. Moreover, digital tools and bioinformatics are enabling in silico epitope mapping that streamlines candidate selection and reduces animal usage. Regulatory bodies are also converging on harmonized guidelines for immunogen validation, purity thresholds, and animal welfare compliance, creating a more predictable approval pathway for antibody reagents.

Additionally, the rise of hybrid immunization protocols-combining primary and booster strategies-has enhanced titer consistency and affinity maturation. Service providers are increasingly adopting ion exchange chromatography and affinity purification techniques to achieve higher antibody purity with minimal cross-reactivity. The acceleration of pandemic-driven R&D and the growing emphasis on personalized medicine have further fueled demand for bespoke antibody panels capable of detecting novel biomarkers. Collectively, these developments are forging a more agile, technology-enabled market that prioritizes speed, specificity, and sustainability, setting a new standard for custom polyclonal antibody production.

Cumulative Impact of United States Tariffs 2025 on Service Providers

The introduction of additional United States tariffs in 2025 has exerted significant pressure on the custom polyclonal antibody value chain. Tariffs on imported adjuvants, chromatography resins, and critical immunology reagents have driven raw material costs upward by double-digit percentages. Delays at customs checkpoints have also extended project timelines, forcing service providers to adjust production schedules and absorb increased warehousing expenses. In response, several leading organizations have accelerated local sourcing initiatives and established domestic supply partnerships for recombinant antigen manufacture and peptide synthesis.

While cost inflation has eroded some margin levers, the tariff regime has simultaneously incentivized investment in onshore manufacturing facilities and animal husbandry operations. By relocating key production nodes closer to end-users, providers can mitigate international shipping risks and improve lead-times for time-sensitive projects. Strategic alliances between reagent suppliers and contract research organizations are also emerging to share the burden of compliance costs and regulatory audits. Although the tariff environment remains a headwind in the near term, these adaptive strategies are strengthening domestic capacity and fostering a more resilient supply chain for custom polyclonal antibody production.

Key Segmentation Insights for Tailored Antibody Solutions

When analyzed by application, diagnostic services lead demand growth, with molecular diagnostics, point-of-care testing, and protein diagnostics driving requirements for highly specific polyclonal sera. Simultaneously, research applications in genomics, metabolomics, and proteomics continue to require bespoke antibody panels for target validation and pathway analysis. In the therapeutic domain, customized antibodies tailored to autoimmune diseases, infectious diseases, and oncology are becoming indispensable for preclinical efficacy studies and biomarker development.

From the end-user industry perspective, academic institutions-spanning colleges, research labs, and universities-prioritize flexible delivery schedules and cost-effective package sizes. Biotechnology companies engaged in experimental testing and product development demand rapid turnaround and scalability, while pharmaceutical organizations, including contract research organizations and in-house production teams, emphasize rigorous documentation and quality management systems. Both private and public sector research institutes are similarly focused on reproducibility and compliance.

Examining the type of animals employed, chickens-broiler and layer varieties-offer large serum volumes for antibody harvesting. Goats, differentiated into dairy and meat breeds, provide high-titer responses against challenging epitopes. Mice models, whether in-bred, out-bred, or transgenic, enable precise immunogenicity studies, and rabbits-both hybrid strains and standard strains-deliver robust antibody diversity.

Across the production process spectrum, antigen selection using recombinant proteins or synthetic peptides lays the foundation, followed by primary and booster immunization schedules that optimize titer and specificity. Down-stream, affinity purification and ion exchange chromatography ensure high purity, while ELISA and hybridoma screening validate performance. Moreover, service type segmentation-from fragmentation services and full-length antibody production to fully human antibody design, single-chain variable fragment development, biotinylation, conjugation, enzyme labeling, and high-throughput screening-provides end-users with tailored solutions for every phase of their workflow.

Regional Dynamics Shaping Service Demand and Growth

In the Americas, established biotech clusters and a robust regulatory framework support high volumes of custom antibody projects across diagnostics, research, and therapeutics. Cost-effective domestic manufacturing and proximity to leading end-users contribute to faster delivery cycles.

Across Europe, the Middle East & Africa, a complex patchwork of regulatory agencies and reimbursement landscapes shapes provider strategies. Harmonization efforts under the European Medicines Agency streamline cross-border collaborations, while Middle Eastern investment in life sciences infrastructure is driving capacity expansion. Africa’s emerging research hubs are beginning to leverage local animal models for region-specific studies, although access to advanced purification technologies remains variable.

Asia-Pacific exhibits the fastest growth trajectory, fueled by government incentives for biotechnology development, expanding clinical trial activity, and investments in automation. Countries with large agricultural sectors are optimizing poultry and livestock immunization processes, while major centers of excellence in China, Japan, South Korea, and India are integrating AI-driven epitope prediction tools with traditional immunization platforms. Manufacturing scale-up in this region is also supported by lower labor costs and favorable export policies for research reagents.

Competitive Landscape and Leading Companies Overview

Abcam Plc continues to leverage its extensive antibody library and reagent ecosystem to enhance service flexibility, while Bio-Rad Laboratories, Inc. invests heavily in automation platforms that accelerate screening and scale-up. BioLegend, Inc. differentiates itself through single-cell analysis collaborations and targeted immunoassays. Creative Biolabs, Inc. excels in custom transgenic animal models and offers integrated immunization and screening services. Cytoskeleton, Inc. focuses on specialized reagents and advanced purification kits that cater to niche research areas.

GenScript Bi Corporation and GenScript Biotech Corporation bolster peptide antigen design and synthesis capabilities, enabling rapid turnaround for novel targets. Pacific Immunology Corp. advances poultry-derived antibody services, optimizing protocols for broiler and layer chickens. ProSci Incorporated integrates hybridoma and ELISA screening pipelines within its custom production workflows. Rockland Immunochemicals Inc. is renowned for high-purity affinity chromatography systems. Thermo Fisher Scientific Inc. provides end-to-end solutions, from antigen validation to final antibody characterization, while USA Peptides focuses on bespoke peptide antigens that feed directly into immunization pipelines. Collectively, these leaders drive innovation, scale, and quality, setting benchmarks for custom polyclonal antibody production services.

Actionable Recommendations for Industry Leaders

To navigate market complexities and capture growth opportunities, industry leaders should prioritize the following actions. First, diversify animal models and reagent portfolios to address emerging research areas, such as multiplexed biomarker panels and immuno-oncology targets. Next, invest in digital platforms for in silico epitope mapping, automated data capture, and remote project monitoring to accelerate decision cycles and enhance transparency.

Furthermore, optimize supply chain resilience by establishing dual sourcing agreements for critical reagents and evaluating onshore manufacturing partnerships to mitigate tariff-driven cost fluctuations. Forge strategic alliances with academic institutions and contract research organizations to co-develop application-specific antibody libraries and share validation resources. Embrace continuous process improvement by integrating real-time analytics in purification and screening workflows, and adopt sustainable practices that reduce animal usage and environmental footprint. Finally, engage proactively with regulatory authorities to shape evolving guidelines, ensuring that quality management systems and documentation practices align with global standards.

Executive Conclusion and Strategic Implications

In summary, custom polyclonal antibody production stands at the intersection of scientific innovation, regulatory evolution, and market diversification. Technological advancements-from recombinant antigen design to high-throughput screening-are driving faster, more reliable outcomes, while emerging tariff dynamics and regional growth patterns compel strategic adaptations in supply chains and service models. A nuanced understanding of segmentation across applications, end users, animal types, production processes, and service categories is essential for providers aiming to differentiate their offerings. By leveraging competitive insights from leading companies and implementing targeted recommendations-such as digital integration, strategic alliances, and regulatory engagement-organizations can secure a sustainable edge in an increasingly complex environment. The synthesis of these factors underscores the critical role of custom polyclonal antibodies in advancing life sciences research, diagnostics, and therapeutic innovation.

Market Segmentation & Coverage

This research report categorizes the Custom Polyclonal Antibody Production Service Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Diagnostics
    • Molecular Diagnostics
    • Point-Of-Care Testing
    • Protein Diagnostics
  • Research
    • Genomics
    • Metabolomics
    • Proteomics
  • Therapeutics
    • Autoimmune Diseases
    • Infectious Diseases
    • Oncology
  • Academic Institutions
    • Colleges
    • Research Labs
    • Universities
  • Biotechnology Companies
    • Experimental Testing
    • Product Development
  • Pharmaceutical Companies
    • Contract Research Organizations
    • In-House Production
  • Research Institutes
    • Private Sector
    • Public Sector
  • Chickens
    • Broiler Chickens
    • Layer Chickens
  • Goats
    • Dairy Goats
    • Meat Goats
  • Mice
    • In-Bred
    • Out-Bred
    • Transgenic
  • Rabbits
    • Hybrid Strains
    • Standard Strains
  • Antigen Selection
    • Recombinant Proteins
    • Synthetic Peptides
  • Immunization
    • Booster Immunization
    • Primary Immunization
  • Purification
    • Affinity Purification
    • Ion Exchange Chromatography
  • Screening
    • ELISA Screening
    • Hybridoma Screening
  • Custom Production Services
    • Fragmentation Services
    • Full-Length Antibody Production
  • Design and Development Services
    • Fully Human Antibodies
    • Single Chain Variable Fragments
  • Modification Services
    • Biotinylation
    • Conjugation Services
  • Non-Standard Services
    • Enzyme Labeling Services
    • High-Throughput Screening

This research report categorizes the Custom Polyclonal Antibody Production Service Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Custom Polyclonal Antibody Production Service Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Abcam Plc
  • Bio-Rad Laboratories, Inc.
  • BioLegend, Inc.
  • Creative Biolabs, Inc.
  • Cytoskeleton, Inc.
  • GenScript Bi Corporation
  • GenScript Biotech Corporation
  • Pacific Immunology Corp.
  • ProSci Incorporated
  • Rockland Immunochemicals Inc.
  • Thermo Fisher Scientific Inc.
  • USA Peptides

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Custom Polyclonal Antibody Production Service Market, by Applications
8.1. Introduction
8.2. Diagnostics
8.2.1. Molecular Diagnostics
8.2.2. Point-Of-Care Testing
8.2.3. Protein Diagnostics
8.3. Research
8.3.1. Genomics
8.3.2. Metabolomics
8.3.3. Proteomics
8.4. Therapeutics
8.4.1. Autoimmune Diseases
8.4.2. Infectious Diseases
8.4.3. Oncology
9. Custom Polyclonal Antibody Production Service Market, by End-User Industry
9.1. Introduction
9.2. Academic Institutions
9.2.1. Colleges
9.2.2. Research Labs
9.2.3. Universities
9.3. Biotechnology Companies
9.3.1. Experimental Testing
9.3.2. Product Development
9.4. Pharmaceutical Companies
9.4.1. Contract Research Organizations
9.4.2. In-House Production
9.5. Research Institutes
9.5.1. Private Sector
9.5.2. Public Sector
10. Custom Polyclonal Antibody Production Service Market, by Type of Animals
10.1. Introduction
10.2. Chickens
10.2.1. Broiler Chickens
10.2.2. Layer Chickens
10.3. Goats
10.3.1. Dairy Goats
10.3.2. Meat Goats
10.4. Mice
10.4.1. In-Bred
10.4.2. Out-Bred
10.4.3. Transgenic
10.5. Rabbits
10.5.1. Hybrid Strains
10.5.2. Standard Strains
11. Custom Polyclonal Antibody Production Service Market, by Production Process
11.1. Introduction
11.2. Antigen Selection
11.2.1. Recombinant Proteins
11.2.2. Synthetic Peptides
11.3. Immunization
11.3.1. Booster Immunization
11.3.2. Primary Immunization
11.4. Purification
11.4.1. Affinity Purification
11.4.2. Ion Exchange Chromatography
11.5. Screening
11.5.1. ELISA Screening
11.5.2. Hybridoma Screening
12. Custom Polyclonal Antibody Production Service Market, by Service Type
12.1. Introduction
12.2. Custom Production Services
12.2.1. Fragmentation Services
12.2.2. Full-Length Antibody Production
12.3. Design and Development Services
12.3.1. Fully Human Antibodies
12.3.2. Single Chain Variable Fragments
12.4. Modification Services
12.4.1. Biotinylation
12.4.2. Conjugation Services
12.5. Non-Standard Services
12.5.1. Enzyme Labeling Services
12.5.2. High-Throughput Screening
13. Americas Custom Polyclonal Antibody Production Service Market
13.1. Introduction
13.2. Argentina
13.3. Brazil
13.4. Canada
13.5. Mexico
13.6. United States
14. Asia-Pacific Custom Polyclonal Antibody Production Service Market
14.1. Introduction
14.2. Australia
14.3. China
14.4. India
14.5. Indonesia
14.6. Japan
14.7. Malaysia
14.8. Philippines
14.9. Singapore
14.10. South Korea
14.11. Taiwan
14.12. Thailand
14.13. Vietnam
15. Europe, Middle East & Africa Custom Polyclonal Antibody Production Service Market
15.1. Introduction
15.2. Denmark
15.3. Egypt
15.4. Finland
15.5. France
15.6. Germany
15.7. Israel
15.8. Italy
15.9. Netherlands
15.10. Nigeria
15.11. Norway
15.12. Poland
15.13. Qatar
15.14. Russia
15.15. Saudi Arabia
15.16. South Africa
15.17. Spain
15.18. Sweden
15.19. Switzerland
15.20. Turkey
15.21. United Arab Emirates
15.22. United Kingdom
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Abcam Plc
16.3.2. Bio-Rad Laboratories, Inc.
16.3.3. BioLegend, Inc.
16.3.4. Creative Biolabs, Inc.
16.3.5. Cytoskeleton, Inc.
16.3.6. GenScript Bi Corporation
16.3.7. GenScript Biotech Corporation
16.3.8. Pacific Immunology Corp.
16.3.9. ProSci Incorporated
16.3.10. Rockland Immunochemicals Inc.
16.3.11. Thermo Fisher Scientific Inc.
16.3.12. USA Peptides
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET MULTI-CURRENCY
FIGURE 2. CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET MULTI-LANGUAGE
FIGURE 3. CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY APPLICATIONS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY APPLICATIONS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY END-USER INDUSTRY, 2024 VS 2030 (%)
FIGURE 10. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY END-USER INDUSTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY TYPE OF ANIMALS, 2024 VS 2030 (%)
FIGURE 12. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY TYPE OF ANIMALS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY PRODUCTION PROCESS, 2024 VS 2030 (%)
FIGURE 14. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY PRODUCTION PROCESS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY SERVICE TYPE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY SERVICE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY POINT-OF-CARE TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY PROTEIN DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY GENOMICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY METABOLOMICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY PROTEOMICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY END-USER INDUSTRY, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY COLLEGES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY RESEARCH LABS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY UNIVERSITIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY ACADEMIC INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY EXPERIMENTAL TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY PRODUCT DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY IN-HOUSE PRODUCTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY PRIVATE SECTOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY PUBLIC SECTOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY TYPE OF ANIMALS, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY CHICKENS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY BROILER CHICKENS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY LAYER CHICKENS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY CHICKENS, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY GOATS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY DAIRY GOATS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY MEAT GOATS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY GOATS, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY MICE, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY IN-BRED, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY OUT-BRED, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY TRANSGENIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY MICE, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY RABBITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY HYBRID STRAINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY STANDARD STRAINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY RABBITS, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY ANTIGEN SELECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY SYNTHETIC PEPTIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY ANTIGEN SELECTION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY IMMUNIZATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY BOOSTER IMMUNIZATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY PRIMARY IMMUNIZATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY IMMUNIZATION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY PURIFICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY AFFINITY PURIFICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY ION EXCHANGE CHROMATOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY PURIFICATION, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY SCREENING, BY REGION, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY ELISA SCREENING, BY REGION, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY HYBRIDOMA SCREENING, BY REGION, 2018-2030 (USD MILLION)
TABLE 74. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
TABLE 75. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 76. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY CUSTOM PRODUCTION SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 77. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY FRAGMENTATION SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 78. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY FULL-LENGTH ANTIBODY PRODUCTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 79. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY CUSTOM PRODUCTION SERVICES, 2018-2030 (USD MILLION)
TABLE 80. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY DESIGN AND DEVELOPMENT SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 81. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY FULLY HUMAN ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 82. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY SINGLE CHAIN VARIABLE FRAGMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 83. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY DESIGN AND DEVELOPMENT SERVICES, 2018-2030 (USD MILLION)
TABLE 84. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY MODIFICATION SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 85. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY BIOTINYLATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 86. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY CONJUGATION SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 87. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY MODIFICATION SERVICES, 2018-2030 (USD MILLION)
TABLE 88. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY NON-STANDARD SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 89. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY ENZYME LABELING SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 90. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY HIGH-THROUGHPUT SCREENING, BY REGION, 2018-2030 (USD MILLION)
TABLE 91. GLOBAL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY NON-STANDARD SERVICES, 2018-2030 (USD MILLION)
TABLE 92. AMERICAS CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 93. AMERICAS CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 94. AMERICAS CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 95. AMERICAS CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 96. AMERICAS CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY END-USER INDUSTRY, 2018-2030 (USD MILLION)
TABLE 97. AMERICAS CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY ACADEMIC INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 98. AMERICAS CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
TABLE 99. AMERICAS CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 100. AMERICAS CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 101. AMERICAS CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY TYPE OF ANIMALS, 2018-2030 (USD MILLION)
TABLE 102. AMERICAS CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY CHICKENS, 2018-2030 (USD MILLION)
TABLE 103. AMERICAS CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY GOATS, 2018-2030 (USD MILLION)
TABLE 104. AMERICAS CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY MICE, 2018-2030 (USD MILLION)
TABLE 105. AMERICAS CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY RABBITS, 2018-2030 (USD MILLION)
TABLE 106. AMERICAS CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
TABLE 107. AMERICAS CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY ANTIGEN SELECTION, 2018-2030 (USD MILLION)
TABLE 108. AMERICAS CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY IMMUNIZATION, 2018-2030 (USD MILLION)
TABLE 109. AMERICAS CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY PURIFICATION, 2018-2030 (USD MILLION)
TABLE 110. AMERICAS CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
TABLE 111. AMERICAS CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 112. AMERICAS CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY CUSTOM PRODUCTION SERVICES, 2018-2030 (USD MILLION)
TABLE 113. AMERICAS CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY DESIGN AND DEVELOPMENT SERVICES, 2018-2030 (USD MILLION)
TABLE 114. AMERICAS CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY MODIFICATION SERVICES, 2018-2030 (USD MILLION)
TABLE 115. AMERICAS CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY NON-STANDARD SERVICES, 2018-2030 (USD MILLION)
TABLE 116. AMERICAS CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 117. ARGENTINA CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 118. ARGENTINA CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 119. ARGENTINA CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 120. ARGENTINA CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 121. ARGENTINA CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY END-USER INDUSTRY, 2018-2030 (USD MILLION)
TABLE 122. ARGENTINA CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY ACADEMIC INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 123. ARGENTINA CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
TABLE 124. ARGENTINA CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 125. ARGENTINA CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 126. ARGENTINA CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY TYPE OF ANIMALS, 2018-2030 (USD MILLION)
TABLE 127. ARGENTINA CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY CHICKENS, 2018-2030 (USD MILLION)
TABLE 128. ARGENTINA CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY GOATS, 2018-2030 (USD MILLION)
TABLE 129. ARGENTINA CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY MICE, 2018-2030 (USD MILLION)
TABLE 130. ARGENTINA CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY RABBITS, 2018-2030 (USD MILLION)
TABLE 131. ARGENTINA CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
TABLE 132. ARGENTINA CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY ANTIGEN SELECTION, 2018-2030 (USD MILLION)
TABLE 133. ARGENTINA CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY IMMUNIZATION, 2018-2030 (USD MILLION)
TABLE 134. ARGENTINA CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY PURIFICATION, 2018-2030 (USD MILLION)
TABLE 135. ARGENTINA CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
TABLE 136. ARGENTINA CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 137. ARGENTINA CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY CUSTOM PRODUCTION SERVICES, 2018-2030 (USD MILLION)
TABLE 138. ARGENTINA CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY DESIGN AND DEVELOPMENT SERVICES, 2018-2030 (USD MILLION)
TABLE 139. ARGENTINA CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY MODIFICATION SERVICES, 2018-2030 (USD MILLION)
TABLE 140. ARGENTINA CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY NON-STANDARD SERVICES, 2018-2030 (USD MILLION)
TABLE 141. BRAZIL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 142. BRAZIL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 143. BRAZIL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 144. BRAZIL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 145. BRAZIL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY END-USER INDUSTRY, 2018-2030 (USD MILLION)
TABLE 146. BRAZIL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY ACADEMIC INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 147. BRAZIL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
TABLE 148. BRAZIL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 149. BRAZIL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 150. BRAZIL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY TYPE OF ANIMALS, 2018-2030 (USD MILLION)
TABLE 151. BRAZIL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY CHICKENS, 2018-2030 (USD MILLION)
TABLE 152. BRAZIL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY GOATS, 2018-2030 (USD MILLION)
TABLE 153. BRAZIL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY MICE, 2018-2030 (USD MILLION)
TABLE 154. BRAZIL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY RABBITS, 2018-2030 (USD MILLION)
TABLE 155. BRAZIL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
TABLE 156. BRAZIL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY ANTIGEN SELECTION, 2018-2030 (USD MILLION)
TABLE 157. BRAZIL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY IMMUNIZATION, 2018-2030 (USD MILLION)
TABLE 158. BRAZIL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY PURIFICATION, 2018-2030 (USD MILLION)
TABLE 159. BRAZIL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
TABLE 160. BRAZIL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 161. BRAZIL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY CUSTOM PRODUCTION SERVICES, 2018-2030 (USD MILLION)
TABLE 162. BRAZIL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY DESIGN AND DEVELOPMENT SERVICES, 2018-2030 (USD MILLION)
TABLE 163. BRAZIL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY MODIFICATION SERVICES, 2018-2030 (USD MILLION)
TABLE 164. BRAZIL CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY NON-STANDARD SERVICES, 2018-2030 (USD MILLION)
TABLE 165. CANADA CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 166. CANADA CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 167. CANADA CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 168. CANADA CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 169. CANADA CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY END-USER INDUSTRY, 2018-2030 (USD MILLION)
TABLE 170. CANADA CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY ACADEMIC INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 171. CANADA CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
TABLE 172. CANADA CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 173. CANADA CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 174. CANADA CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY TYPE OF ANIMALS, 2018-2030 (USD MILLION)
TABLE 175. CANADA CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY CHICKENS, 2018-2030 (USD MILLION)
TABLE 176. CANADA CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY GOATS, 2018-2030 (USD MILLION)
TABLE 177. CANADA CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY MICE, 2018-2030 (USD MILLION)
TABLE 178. CANADA CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY RABBITS, 2018-2030 (USD MILLION)
TABLE 179. CANADA CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
TABLE 180. CANADA CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY ANTIGEN SELECTION, 2018-2030 (USD MILLION)
TABLE 181. CANADA CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY IMMUNIZATION, 2018-2030 (USD MILLION)
TABLE 182. CANADA CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY PURIFICATION, 2018-2030 (USD MILLION)
TABLE 183. CANADA CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
TABLE 184. CANADA CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 185. CANADA CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY CUSTOM PRODUCTION SERVICES, 2018-2030 (USD MILLION)
TABLE 186. CANADA CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY DESIGN AND DEVELOPMENT SERVICES, 2018-2030 (USD MILLION)
TABLE 187. CANADA CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY MODIFICATION SERVICES, 2018-2030 (USD MILLION)
TABLE 188. CANADA CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY NON-STANDARD SERVICES, 2018-2030 (USD MILLION)
TABLE 189. MEXICO CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 190. MEXICO CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 191. MEXICO CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 192. MEXICO CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 193. MEXICO CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY END-USER INDUSTRY, 2018-2030 (USD MILLION)
TABLE 194. MEXICO CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY ACADEMIC INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 195. MEXICO CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
TABLE 196. MEXICO CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 197. MEXICO CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 198. MEXICO CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY TYPE OF ANIMALS, 2018-2030 (USD MILLION)
TABLE 199. MEXICO CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY CHICKENS, 2018-2030 (USD MILLION)
TABLE 200. MEXICO CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY GOATS, 2018-2030 (USD MILLION)
TABLE 201. MEXICO CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY MICE, 2018-2030 (USD MILLION)
TABLE 202. MEXICO CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY RABBITS, 2018-2030 (USD MILLION)
TABLE 203. MEXICO CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
TABLE 204. MEXICO CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY ANTIGEN SELECTION, 2018-2030 (USD MILLION)
TABLE 205. MEXICO CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY IMMUNIZATION, 2018-2030 (USD MILLION)
TABLE 206. MEXICO CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY PURIFICATION, 2018-2030 (USD MILLION)
TABLE 207. MEXICO CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
TABLE 208. MEXICO CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 209. MEXICO CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY CUSTOM PRODUCTION SERVICES, 2018-2030 (USD MILLION)
TABLE 210. MEXICO CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY DESIGN AND DEVELOPMENT SERVICES, 2018-2030 (USD MILLION)
TABLE 211. MEXICO CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY MODIFICATION SERVICES, 2018-2030 (USD MILLION)
TABLE 212. MEXICO CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY NON-STANDARD SERVICES, 2018-2030 (USD MILLION)
TABLE 213. UNITED STATES CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 214. UNITED STATES CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 215. UNITED STATES CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 216. UNITED STATES CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 217. UNITED STATES CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY END-USER INDUSTRY, 2018-2030 (USD MILLION)
TABLE 218. UNITED STATES CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY ACADEMIC INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 219. UNITED STATES CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
TABLE 220. UNITED STATES CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 221. UNITED STATES CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 222. UNITED STATES CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY TYPE OF ANIMALS, 2018-2030 (USD MILLION)
TABLE 223. UNITED STATES CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY CHICKENS, 2018-2030 (USD MILLION)
TABLE 224. UNITED STATES CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY GOATS, 2018-2030 (USD MILLION)
TABLE 225. UNITED STATES CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY MICE, 2018-2030 (USD MILLION)
TABLE 226. UNITED STATES CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY RABBITS, 2018-2030 (USD MILLION)
TABLE 227. UNITED STATES CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
TABLE 228. UNITED STATES CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY ANTIGEN SELECTION, 2018-2030 (USD MILLION)
TABLE 229. UNITED STATES CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY IMMUNIZATION, 2018-2030 (USD MILLION)
TABLE 230. UNITED STATES CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY PURIFICATION, 2018-2030 (USD MILLION)
TABLE 231. UNITED STATES CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
TABLE 232. UNITED STATES CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 233. UNITED STATES CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY CUSTOM PRODUCTION SERVICES, 2018-2030 (USD MILLION)
TABLE 234. UNITED STATES CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY DESIGN AND DEVELOPMENT SERVICES, 2018-2030 (USD MILLION)
TABLE 235. UNITED STATES CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY MODIFICATION SERVICES, 2018-2030 (USD MILLION)
TABLE 236. UNITED STATES CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY NON-STANDARD SERVICES, 2018-2030 (USD MILLION)
TABLE 237. UNITED STATES CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 238. ASIA-PACIFIC CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 239. ASIA-PACIFIC CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 240. ASIA-PACIFIC CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 241. ASIA-PACIFIC CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 242. ASIA-PACIFIC CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY END-USER INDUSTRY, 2018-2030 (USD MILLION)
TABLE 243. ASIA-PACIFIC CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY ACADEMIC INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 244. ASIA-PACIFIC CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
TABLE 245. ASIA-PACIFIC CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 246. ASIA-PACIFIC CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 247. ASIA-PACIFIC CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY TYPE OF ANIMALS, 2018-2030 (USD MILLION)
TABLE 248. ASIA-PACIFIC CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY CHICKENS, 2018-2030 (USD MILLION)
TABLE 249. ASIA-PACIFIC CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY GOATS, 2018-2030 (USD MILLION)
TABLE 250. ASIA-PACIFIC CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY MICE, 2018-2030 (USD MILLION)
TABLE 251. ASIA-PACIFIC CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY RABBITS, 2018-2030 (USD MILLION)
TABLE 252. ASIA-PACIFIC CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
TABLE 253. ASIA-PACIFIC CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY ANTIGEN SELECTION, 2018-2030 (USD MILLION)
TABLE 254. ASIA-PACIFIC CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY IMMUNIZATION, 2018-2030 (USD MILLION)
TABLE 255. ASIA-PACIFIC CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY PURIFICATION, 2018-2030 (USD MILLION)
TABLE 256. ASIA-PACIFIC CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
TABLE 257. ASIA-PACIFIC CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 258. ASIA-PACIFIC CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY CUSTOM PRODUCTION SERVICES, 2018-2030 (USD MILLION)
TABLE 259. ASIA-PACIFIC CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY DESIGN AND DEVELOPMENT SERVICES, 2018-2030 (USD MILLION)
TABLE 260. ASIA-PACIFIC CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY MODIFICATION SERVICES, 2018-2030 (USD MILLION)
TABLE 261. ASIA-PACIFIC CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY NON-STANDARD SERVICES, 2018-2030 (USD MILLION)
TABLE 262. ASIA-PACIFIC CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 263. AUSTRALIA CUSTOM POLYCLONAL ANTIBODY PRODUCTION SE

Companies Mentioned

  • Abcam Plc
  • Bio-Rad Laboratories, Inc.
  • BioLegend, Inc.
  • Creative Biolabs, Inc.
  • Cytoskeleton, Inc.
  • GenScript Bi Corporation
  • GenScript Biotech Corporation
  • Pacific Immunology Corp.
  • ProSci Incorporated
  • Rockland Immunochemicals Inc.
  • Thermo Fisher Scientific Inc.
  • USA Peptides

Methodology

Loading
LOADING...

Related Topics

Related Reports

Polyclonal Antibodies - Global Strategic Business Report - Product Image

Polyclonal Antibodies - Global Strategic Business Report

  • Report
  • 63 Pages
  • Global
From
Custom Antibody Global Market Report 2025 - Product Image

Custom Antibody Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Custom Antibody Development & Production Service Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030 - Product Image

Custom Antibody Development & Production Service Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • Report
  • 184 Pages
  • Global, United States Global, United States
From
Mammalian Polyclonal IgG Antibody Market by Source, Product, Application, End-User - Global Forecast 2025-2030 - Product Image

Mammalian Polyclonal IgG Antibody Market by Source, Product, Application, End-User - Global Forecast 2025-2030

  • Report
  • 191 Pages
  • Global
From
Custom Antibody - Global Strategic Business Report - Product Image

Custom Antibody - Global Strategic Business Report

  • Report
  • 127 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.